TRACON Pharmaceuticals Priced, Nasdaq: TCON

Developing combination therapies with VEGF inhibitors to treat cancers.

Industry: Health Care

Latest Trade: $2.20 0.00 (0.0%)

First Day Return: -6.0%

Return from IPO: -78.0%

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Endoglin is essential to angiogenesis, the process of new blood vessel formation, and a key contributor to the development of fibrosis, or tissue scarring. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In March 2014, Santen Pharmaceutical, a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our anti-endoglin antibodies for ophthalmology indications, including AMD. We retain global rights to develop and commercialize our anti-endoglin antibodies outside of the field of ophthalmology, as well as global rights to TRC102 in all indications.
more less
IPO News for TRACON Pharmaceuticals
more
IPO Data
IPO File Date 12/29/2014
Offer Price $10.00
Price Range $12.00 - $14.00
Offer Shares (mm) 3.6
Deal Size ($mm) $36
IPO Data
IPO Date 01/29/2015
Offer Price $10.00
Price Range $12.00 - $14.00
Offer Shares (mm) 3.6
Deal Size ($mm) $36
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2004
Employees 13
Website www.traconpharma.com